Indegene launches new entity in Spain

Bengaluru: Indegene, a digital-life sciences commercialization company, has announced the launch of a new entity in Spain.

"This move marks a key step in the company’s ongoing strategic expansion in Europe and aligns with Indegene’s commitment to helping life sciences companies accelerate AI-driven innovation and make their operations future-ready. Indegene’s new Spain entity will serve as a key delivery hub for its Europe-based clients, helping them drive hyper-personalization and significantly elevate HCP and patient experience," it said.

“Growing R&D investments, a thriving life sciences innovation ecosystem and a high-quality talent pool make Spain a vital market and talent hub for life sciences companies in Europe”, said Manish Gupta, Chairman and CEO, Indegene. “With our new entity in Spain, we can co-innovate and collaborate much better with clients, helping them use data and AI more effectively to modernize commercialization processes and fast-track business transformation.”

Indegene already has a significant presence in Europe, with centers in the UK, Germany, Ireland and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

Read also: Shares of Indegene listed with nearly 46 percent premium

In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. Indegene supports many life sciences clients in the region in various ways across the commercialization value chain. With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. 

Read also: Carlyle Group divests 4.3% stake in Indegene for Rs 636 crore